These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12202899)

  • 1. [Doxorubicin and paclitaxel vs. 5-fluorouracyl, doxorubicin and cyclophosphamid in the first line treatment of metastatic breast cancer].
    Nagykálnai T
    Magy Onkol; 2002; 46(2):192-3. PubMed ID: 12202899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
    Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
    J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer.
    Di Leo A; Piccart MJ
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):27-32. PubMed ID: 10403471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
    Bottomley A; Biganzoli L; Cufer T; Coleman RE; Coens C; Efficace F; Calvert HA; Gamucci T; Twelves C; Fargeot P; Piccart M;
    J Clin Oncol; 2004 Jul; 22(13):2576-86. PubMed ID: 15226325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer.
    Kaufman PA
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):39-46. PubMed ID: 10403473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer.
    Hortobagyi GN; Holmes FA
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S4-7. PubMed ID: 9071332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer.
    Akhtar MS; Kousar F; Masood M; Fatimi S; Kokab
    J Coll Physicians Surg Pak; 2010 Nov; 20(11):748-52. PubMed ID: 21078249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial.
    Jassem J; Pienkowski T; Pluzanska A; Jelic S; Gorbunova V; Berzins J; Nagykalnai T; Biganzoli L; Aloe A; Astier L; Munier S
    Onkologie; 2009 Sep; 32(8-9):468-72. PubMed ID: 19745590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
    Schmid P; Schippinger W; Nitsch T; Huebner G; Heilmann V; Schultze W; Hausmaninger H; Wischnewsky M; Possinger K
    J Clin Oncol; 2005 Jan; 23(3):432-40. PubMed ID: 15659490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
    Green MC; Buzdar AU; Smith T; Ibrahim NK; Valero V; Rosales MF; Cristofanilli M; Booser DJ; Pusztai L; Rivera E; Theriault RL; Carter C; Frye D; Hunt KK; Symmans WF; Strom EA; Sahin AA; Sikov W; Hortobagyi GN
    J Clin Oncol; 2005 Sep; 23(25):5983-92. PubMed ID: 16087943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel and doxorubicin in metastatic breast cancer.
    Gehl J; Boesgaard M; Paaske T; Jensen BV; Dombernowsky P
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):35-8. PubMed ID: 8996596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies.
    Sledge GW
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):57-9. PubMed ID: 8893901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
    Nagykálnai T
    Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
    Gianni L; Baselga J; Eiermann W; Guillem Porta V; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Llombart Cussac A; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez Lopez JJ; Mansutti M; Valagussa P; Bonadonna G;
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8715-21. PubMed ID: 16361558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and epidoxorubicin as first-line chemotherapy for metastatic breast carcinoma: a randomised phase II study.
    Gebbia V; Blasi L; Borsellino N; Caruso M; Leonardi V; Agostara B; Valenza R
    Anticancer Res; 2003; 23(1B):765-71. PubMed ID: 12680181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel combination therapy in the treatment of metastatic breast cancer.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):29-39. PubMed ID: 8941408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
    Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey.
    Paridaens R
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):3-6. PubMed ID: 9865704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.